• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The efficacy of dalbavancin and impact on hospitalization and treatment costs in patients with ABSSSI.达巴万星治疗急性细菌性皮肤和皮肤结构感染（ABSSSI）患者的疗效及其对住院和治疗费用的影响。
Glob Reg Health Technol Assess. 2024 Jul 29;11(Suppl 2):13-17. doi: 10.33393/grhta.2024.3045. eCollection 2024 Jan-Dec.
2
Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries.在三个欧洲国家治疗急性细菌性皮肤和皮肤结构感染的达巴万星预算影响分析。
Clin Drug Investig. 2020 Apr;40(4):305-318. doi: 10.1007/s40261-020-00891-w.
3
Dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients: a case series.达巴万星治疗儿科患者急性细菌性皮肤和皮肤结构感染（ABSSSI）：病例系列
Infez Med. 2024 Jun 1;32(2):231-240. doi: 10.53854/liim-3202-11. eCollection 2024.
4
Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study).达巴万星治疗急性细菌性皮肤和皮肤结构感染（ABSSSIs）和其他感染的疗效和安全性：来自意大利观察性多中心研究（DALBITA 研究）的数据。
Expert Rev Anti Infect Ther. 2020 Dec;18(12):1271-1279. doi: 10.1080/14787210.2020.1798227. Epub 2020 Aug 14.
5
Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease network.达巴万星与传染病网络中标准治疗方案对比的临床、组织及药物经济学视角
Glob Reg Health Technol Assess. 2024 Jul 29;11(Suppl 2):5-12. doi: 10.33393/grhta.2024.3094. eCollection 2024 Jan-Dec.
6
Direct or early Discharge of Acute Bacterial Skin and Skin Structure Infection patients from the Emergency Department/Unit: place in therapy of dalbavancin.直接或早期从急诊科/病房出院的急性细菌性皮肤和皮肤结构感染患者：将达巴万星纳入治疗方案。
Expert Rev Anti Infect Ther. 2023 Jul-Dec;21(7):703-721. doi: 10.1080/14787210.2023.2214727. Epub 2023 May 31.
7
REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI.REDS研究：达巴万星与其他相同静脉注射抗生素类别的标准治疗方案对急性细菌性皮肤和皮肤结构感染（ABSSSI）患者的回顾性疗效研究。
Int J Antimicrob Agents. 2023 Apr;61(4):106746. doi: 10.1016/j.ijantimicag.2023.106746. Epub 2023 Feb 8.
8
Cost-Consequence Analysis of Single-Dose Dalbavancin Versus Standard of Care for the Treatment of Acute Bacterial Skin and Skin Structure Infections in a Multisite Healthcare System.单剂量达巴万星与标准治疗方案治疗多地点医疗机构中急性细菌性皮肤和皮肤结构感染的成本-后果分析。
Clin Infect Dis. 2021 Oct 5;73(7):e1436-e1442. doi: 10.1093/cid/ciaa1732.
9
The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).达巴万星在治疗急性细菌性皮肤和皮肤结构感染（ABSSSIs）中的作用。
Expert Rev Anti Infect Ther. 2020 May;18(5):415-422. doi: 10.1080/14787210.2020.1746643. Epub 2020 Mar 29.
10
Real-World Use of Dalbavancin for Treatment of Soft Tissue and Bone Infection in Children: Safe, Effective and Hospital-Time Sparing.达巴万星在儿童软组织和骨感染治疗中的真实世界应用：安全、有效且节省住院时间
Children (Basel). 2024 Jan 9;11(1):78. doi: 10.3390/children11010078.

本文引用的文献

1
Direct or early Discharge of Acute Bacterial Skin and Skin Structure Infection patients from the Emergency Department/Unit: place in therapy of dalbavancin.直接或早期从急诊科/病房出院的急性细菌性皮肤和皮肤结构感染患者：将达巴万星纳入治疗方案。
Expert Rev Anti Infect Ther. 2023 Jul-Dec;21(7):703-721. doi: 10.1080/14787210.2023.2214727. Epub 2023 May 31.
2
Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals.在两家意大利医院中，达巴万星与标准治疗方案治疗急性细菌性皮肤和皮肤结构感染（ABSSSIs）的成本分析。
JAC Antimicrob Resist. 2023 Apr 19;5(2):dlad044. doi: 10.1093/jacamr/dlad044. eCollection 2023 Apr.
3
REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI.REDS研究：达巴万星与其他相同静脉注射抗生素类别的标准治疗方案对急性细菌性皮肤和皮肤结构感染（ABSSSI）患者的回顾性疗效研究。
Int J Antimicrob Agents. 2023 Apr;61(4):106746. doi: 10.1016/j.ijantimicag.2023.106746. Epub 2023 Feb 8.
4
Real world utilization of Dalbavancin at a rural community emergency department.在农村社区急诊部使用达巴万星的真实世界研究。
Am J Emerg Med. 2022 Apr;54:253-256. doi: 10.1016/j.ajem.2022.02.006. Epub 2022 Feb 6.
5
Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections.达巴万星治疗不同革兰阳性菌感染的疗效及其对住院时间和治疗费用的影响。
Clin Drug Investig. 2021 May;41(5):437-448. doi: 10.1007/s40261-021-01028-3. Epub 2021 Apr 21.
6
Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization.综述：达巴万星用于适应证及超适应证使用的安全性概况
Ther Clin Risk Manag. 2021 Mar 22;17:223-232. doi: 10.2147/TCRM.S271445. eCollection 2021.
7
Pathway with single-dose long-acting intravenous antibiotic reduces emergency department hospitalizations of patients with skin infections.单剂长效静脉抗生素治疗途径可减少皮肤感染患者的急诊住院次数。
Acad Emerg Med. 2021 Oct;28(10):1108-1117. doi: 10.1111/acem.14258. Epub 2021 May 5.
8
Effectiveness, safety and cost analysis of dalbavancin in clinical practice.达巴万星在临床实践中的有效性、安全性和成本分析。
Eur J Hosp Pharm. 2022 Jan;29(1):55-58. doi: 10.1136/ejhpharm-2020-002315. Epub 2020 Oct 5.
9
Current trends in the real-life use of dalbavancin: report of a study panel.临床应用达巴万星的现状：研究小组报告。
Int J Antimicrob Agents. 2020 Oct;56(4):106107. doi: 10.1016/j.ijantimicag.2020.106107. Epub 2020 Jul 25.
10
Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries.在三个欧洲国家治疗急性细菌性皮肤和皮肤结构感染的达巴万星预算影响分析。
Clin Drug Investig. 2020 Apr;40(4):305-318. doi: 10.1007/s40261-020-00891-w.

达巴万星治疗急性细菌性皮肤和皮肤结构感染（ABSSSI）患者的疗效及其对住院和治疗费用的影响。

The efficacy of dalbavancin and impact on hospitalization and treatment costs in patients with ABSSSI.

作者信息

Carbonara Sergio

机构信息

Unità Operativa Complessa di Malattie Infettive, Ospedale Vittorio Emanuele II, Bisceglie - Italy.

出版信息

Glob Reg Health Technol Assess. 2024 Jul 29;11(Suppl 2):13-17. doi: 10.33393/grhta.2024.3045. eCollection 2024 Jan-Dec.

DOI:10.33393/grhta.2024.3045
PMID:39100524
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11292618/
Abstract

Acute bacterial skin and skin structure infections (ABSSSIs) represent a common and costly healthcare burden, accounting for millions of annual infections and billions of dollars in healthcare expenditures. Dalbavancin is a long-acting glycopeptide antibiotic that has demonstrated efficacy and safety in the treatment of ABSSSIs. This review article will examine the efficacy of dalbavancin and focus on its impact on the hospital length of stay and costs associated with management of these infections.

摘要

急性细菌性皮肤和皮肤结构感染（ABSSSIs）是一种常见且成本高昂的医疗负担，每年导致数百万例感染，医疗支出达数十亿美元。达巴万星是一种长效糖肽类抗生素，已证明在治疗ABSSSIs方面具有疗效和安全性。这篇综述文章将研究达巴万星的疗效，并重点关注其对住院时间以及这些感染管理相关成本的影响。